| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| ACADIA Pharmaceuticals, Inc. |
| 3911 Sorento Valley Boulevard, San Diego, CA 92121 * (858) 558-2871 |
| Business Description | The company is a genomics based drug discovery and development company that efficiently identifies target-specific small molecule drug candidates using an integrated technology platform. |
|
Filing Information Not yet | |||
| To Trade As | ACAD (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 12/21/2000 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1995 | 12/31/1996 | 12/31/1997 | 12/31/1998 | 12/31/1999 | 9/30/1999 | 9/30/2000 |
| Revenues | 0.300 | 0.438 | 0.835 | 1.419 | 2.238 | 1.334 | 2.768 |
| Income from Oper. | -0.049 | -0.189 | -3.231 | -6.924 | -7.845 | -6.244 | -8.474 |
| Net Income | -0.052 | -0.192 | -2.982 | -6.403 | -7.445 | -5.906 | -7.754 |
| E.P.S | -0.030 | -0.130 | -1.740 | -3.120 | -3.570 | -2.830 | -3.630 |
| Revenue Growth (%) | 46.00 | 90.64 | 69.94 | 57.717 | 107.50 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.98 | -4.65 | -4.46 | ||||
| Cash Flow - Inv. | 3.15 | 3.67 | -12.04 | ||||
| Cash Flow - Fin. | 1.83 | 1.03 | 23.14 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2000 | Financial Ratios | ||||
| Total Assets | 33.47 | Current Assets | 30.12 | Current Ratio | 10.15 |
| Total Liab. | 54.10 | Current Liab. | 2.97 | Debt Ratio | 161.64% |
| Total Equity | -20.63 | Working Cap. | 27.15 | Debt to Equity Ratio | - |
| Cash | 10.22 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, capital expenditures, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Brobeck Hale and Dorr International |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Kommunernes Pensionsforsikring | 13.50 | |
| Danske Kapitalanlaeg Aktieselskab | 13.50 | |
| Lonmodtagernes Dyrtidsfond | 12.30 | |
| Allergan Sales, Inc. and affiliates | 9.30 | |
| BankInvest affiliates | 8.10 | |
| S.V. Penelope Jones B.V. | 7.70 | |
| ABN AMRO Ventures B.V. | 7.00 | |
| OrbiMed Advisors LLC affiliates | 6.20 | |
| Hambrecht & Quist Capital Management, Inc. | 6.20 | |
| Note: represents ownership of 5% or more prior to the offering. | ||